SOLIDARITY Finland Plus Long-COVID

Launched by CLINICAL UROLOGY AND EPIDEMIOLOGY WORKING GROUP · Feb 1, 2022

Keywords

ClinConnect Summary

The SOLIDARITY Finland Plus Long-COVID trial is studying how two medications, imatinib and infliximab, might help reduce long-term symptoms of COVID-19 in people who were hospitalized with the virus. Researchers want to find out if these drugs can lower the chances of developing long-COVID symptoms—issues like fatigue, memory problems, anxiety, and other health concerns that persist after recovery—and improve quality of life. Patients will be asked to complete questionnaires about their symptoms and overall health at six months, one year, and two years after leaving the hospital.

To participate in this trial, you need to be an adult aged 18 or older who has had a confirmed COVID-19 infection and was admitted to the hospital. You will need to provide written consent, or a family member can give consent if you are unable to do so. The trial will involve regular check-ins to assess your health, and it aims to gather valuable information to better understand the long-term effects of COVID-19 and how to treat them effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients, 18 years and above
• • SARS-2-CoV-2 infection, laboratory-confirmed
• • Admission to the hospital ward or ICU
• • Written informed consent prior to initiation of the study or a close relative/legal representative provides written informed consent prior to initiation of the study according to the presumed will of the patient when the patient is unable to give consent herself/himself.
• • No anticipated transfer within 72 hours to a non-study hospital
• Exclusion Criteria:
• • Estimated life expectancy under three months due to severe comorbidity
• • ASAT/ALAT-ratio over five-fold upper limit
• • Acute myocardial infarction or unstable angina pectoris
• • Breast feeding or pregnancy
• • Any reason why, in the opinion of the investigators, the patient should not participate
• • Patient participates in a potentially confounding drug or device trial during the course of the study
• • Already receiving any of the study drugs
• • Severe renal failure (eGFR \< 30 mL/min)